Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsBruce Strober, MD, PhD, FAAD
Clinical ProfessorAbout
Research
Publications
2026
Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity
Lebwohl M, Blauvelt A, Kartman C, Leatherwood C, Gordon K, Sattar N, Puig L, Merola J, Siu K, Wang R, Sun L, Leung A, Somani N, Rueda M, Cardoso A, Genovese M, Armstrong A, Strober B. Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity. JAMA Dermatology 2026, e261753. PMID: 42139049, PMCID: PMC13179568, DOI: 10.1001/jamadermatol.2026.1753.Peer-Reviewed Original ResearchClinical trialsWeight reductionActive-controlled clinical trialSafety of ixekizumabSevere plaque psoriasisAdjunct to dietWeight-related comorbiditiesInjection site reactionsDrug safety profileElevate careStatistically significant improvementOpen-labelPlaque psoriasisSevere psoriasisSkin clearancePsoriasis activityMain OutcomesPhase 3bSite reactionsIxekizumabSafety profileClinical outcomesCardiometabolic benefitsTreatment responseAdverse eventsSummary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial
Langley R, Arkin L, Fiorillo L, Eichenfield L, Lebwohl M, Strober B, Sticherling M, Swanson L, Kokolakis G, Chaudhari S, Deignan C, Zhang Z, Paller A. Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial. Dermatology And Therapy 2026, 16: 2229-2232. PMID: 42133282, PMCID: PMC13219672, DOI: 10.1007/s13555-026-01714-0.Peer-Reviewed Original ResearchPhase 3 trialDisease durationModerate to severe PsOSkin outcomesSevere plaque psoriasisEfficacy of apremilastShorter disease durationPost Hoc AnalysisSystemic therapyPlaque psoriasisTopical therapyPediatric patientsBaseline characteristicsApremilastPatientsHoc AnalysisAged 6Disease burdenPlaceboDiseaseWeeksTherapyEarly interventionOutcomesDurationEnvudeucitinib, a Potent, Next-Generation, Allosteric Inhibitor of TYK2: A Narrative Review
Armstrong A, Krueger J, Strober B, Stein Gold L, Desai S, Muscianisi E, Klyachkin Y, Ucpinar S, Tilley M, Blauvelt A. Envudeucitinib, a Potent, Next-Generation, Allosteric Inhibitor of TYK2: A Narrative Review. Dermatology And Therapy 2026, 16: 2661-2673. PMID: 41934538, PMCID: PMC13237387, DOI: 10.1007/s13555-026-01727-9.Peer-Reviewed Original ResearchImmune-mediated inflammatory diseasesElevated systemic levelsTyrosine kinase 2I interferonInflammation associated with psoriasisSystemic levels of inflammatory cytokinesOral administrationI interferon gene signatureInhibition of tyrosine kinase 2Tyrosine kinase 2 inhibitionPhase 2 studyLevels of inflammatory cytokinesPhase 1 studyInterleukin (IL)-23Systemic lupus erythematosusTreatment of psoriasisJanus kinaseType I interferonLong-term usePlaque psoriasisOral immunomodulatorBiologic therapyT cellsSafety profileLupus erythematosusReply to Woodie et al, “Elevated risk of active tuberculosis with interleukin (IL)-17, IL-23, IL-12/23, Janus kinase inhibitors, cyclosporine, and tumor necrosis factor-α inhibitors compared with the general population: A population-based analysis using TriNetX”
Torres T, Blauvelt A, Strober B, van de Kerkhof P, Eakin G, Winthrop K, Gelfand J. Reply to Woodie et al, “Elevated risk of active tuberculosis with interleukin (IL)-17, IL-23, IL-12/23, Janus kinase inhibitors, cyclosporine, and tumor necrosis factor-α inhibitors compared with the general population: A population-based analysis using TriNetX”. Journal Of The American Academy Of Dermatology 2026, 95: e71-e72. PMID: 41850622, DOI: 10.1016/j.jaad.2025.12.129.Commentaries, Editorials and LettersThe Role and Risks of Systemic Corticosteroids in Atopic Dermatitis: An Expert Consensus
Burshtein J, Bunick C, Vleugels R, Armstrong A, Golant A, Schlesinger T, Strober B, Song E, Stein Gold L, Shah M, DeBusk L, Rosenberg A, Bartley B, Zakria D, Lebwohl M. The Role and Risks of Systemic Corticosteroids in Atopic Dermatitis: An Expert Consensus. SKIN The Journal Of Cutaneous Medicine 2026, 10: s724. DOI: 10.25251/3j4scd05.Peer-Reviewed Original ResearchSystemic corticosteroidsStrength of Recommendation TaxonomyAtopic dermatitisExpert consensusConsensus statementSystemic corticosteroid exposureSystemic therapy trialsLiterature searchManagement of ADChronic inflammatory diseaseAdvanced systemic treatmentsComprehensive literature searchStrength of recommendationsSystemic treatmentTherapy trialsInflammatory diseasesAlternative therapiesEvidence-based thresholdsCorticosteroidsRoutine useRecommendation TaxonomyCombination of keywordsDermatitisEligible articlesAdverse effectsBimekizumab Remission and High Disease Control Over 4 years in Patients with Psoriasis Achieving Complete Skin Clearance at Week 16: Results from Four Phase 3 Trials
Warren R, Strober B, Jullien D, Lebwohl M, Eyerich K, Langley R, Szilagyi B, Warham R, Armstrong A. Bimekizumab Remission and High Disease Control Over 4 years in Patients with Psoriasis Achieving Complete Skin Clearance at Week 16: Results from Four Phase 3 Trials. SKIN The Journal Of Cutaneous Medicine 2026, 10: s758. DOI: 10.25251/0bnq3318.Peer-Reviewed Original ResearchOpen-label extensionPercentage of patientsPhase 3 trialSkin clearanceProcedural dataStudy visitsDisease controlTreatment due to lackYear 4Remission of psoriasisComplete skin clearanceBimekizumabAdverse eventsNon-respondersTreatment guidelinesPASIQ8WBE SUREPatientsHigher disease controlLong-term maintenancePsoriasisQ4WRemissionWeeksApremilast improves skin outcomes in pediatric plaque psoriasis of shorter disease duration: 52-week results from the SPROUT phase 3 trial
Langley R, Arkin L, Fiorillo L, Eichenfield L, Lebwohl M, Strober B, Sticherling M, Swanson L, Kokolakis G, Chaudhari S, Deignan C, Zhang Z, Paller A. Apremilast improves skin outcomes in pediatric plaque psoriasis of shorter disease duration: 52-week results from the SPROUT phase 3 trial. Journal Of The American Academy Of Dermatology 2026, 94: 1777-1780. PMID: 41643746, DOI: 10.1016/j.jaad.2026.01.072.Peer-Reviewed Original ResearchIn Memoriam: Wayne Peter Francis Gulliver, MD, FRCPC (March 4, 1958-September 5, 2025)
Strober B. In Memoriam: Wayne Peter Francis Gulliver, MD, FRCPC (March 4, 1958-September 5, 2025). Journal Of The American Academy Of Dermatology 2026, 94: e139-e140. DOI: 10.1016/j.jaad.2025.10.060.Peer-Reviewed Original ResearchBrodalumab's 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World Evidence.
Lebwohl M, Krueger J, Koo J, Han G, Armstrong A, Strober B, Kircik L. Brodalumab's 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World Evidence. Journal Of Drugs In Dermatology 2026, 25: 211-220. PMID: 41779761, DOI: 10.36849/jdd.9739.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsReal-world studyPlaque psoriasisClinical trialsRate of complete responseModerate-to-severe psoriasisChronic immune-mediated diseaseSafety of brodalumabLong-term clinical trialsRisk of malignancyAdverse cardiac eventsFatal adverse eventsHuman monoclonal antibodyImmune-mediated diseasesDisease controlComplete responseSystemic therapySkin clearanceTherapeutic optionsCardiac eventsSafety profileSustained disease controlAdverse eventsBrodalumabInterleukin-17Proinflammatory cytokinesThe role and risks of systemic corticosteroids in atopic dermatitis: an expert consensus
Burshtein J, Bunick C, Vleugels R, Armstrong A, K. Golant A, Schlesinger T, Strober B, Song E, Gold L, Shah M, DeBusk L, Rosenberg A, Bartley B, Zakria D, Lebwohl M. The role and risks of systemic corticosteroids in atopic dermatitis: an expert consensus. Archives Of Dermatological Research 2026, 318: 44. DOI: 10.1007/s00403-025-04502-6.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSystemic corticosteroid exposureSystemic corticosteroidsStrength of Recommendation TaxonomyAtopic dermatitisSystemic therapyLong-term disease controlConsensus statementDuration-dependent toxicitySteroid-sparing optionsSystemic therapy trialsAssociated with serious adverse eventsLong-term benefit-risk profileModerate-to-severe ADSerious adverse eventsBenefit-risk profileExpert consensusChronic inflammatory diseaseAdvanced systemic treatmentsComprehensive literature searchFoundational therapySystemic treatmentTherapy trialsAdverse eventsIntramuscular doseGuideline recommendations